©2019 by HALO Diagnostics

Multiparametric Magnetic Resonance Imaging (mpMRI) - Timely and Accurate Detection

Serving Patients Since 1998

mpMRI (with or without biopsies) is a recent paradigm shift in the diagnosis and management of prostate cancer. It is a game-changing medical breakthrough for the urologic community.

 

As the name suggests it includes a number of different features using MRI to look at the prostate. This is very effective at early detection of tumor suspicious regions. Multiparametric-MRI includes

 

T2-weighted imaging

Diffusion-weighted imaging (DWI)

Dynamic contrast-enhanced (DCE) imaging

Combined together with the serum prostate-specific antigen (PSA) tests, it facilitates precise diagnosis, monitoring, and management of prostate cancer.

This means it will benefit men who go undiagnosed and remain under active surveillance or watchful waiting, without timely appropriate treatment.

Find out if mpMRI is a good option for you!

mpMRI involves multiple MR-guided features for timely and precise prostate imaging. It is particularly informative for the following conditions

A. Clinical suspicion of prostate cancer 

Prostate-specific antigen (PSA) levels in the blood >4 ng/ml, abnormal digital rectal exam, and no prior history of prostate biopsy

Active surveillance in patients with Gleason score 6 or grade group 1 and PSA <10 ng/ml

B. Managing prostate cancer in patients post-treatment

Biochemical recurrence of prostate cancer following treatment (prostatectomy or radiation)

T2-weighted imaging

T2-weighted imaging provides detailed anatomical and morphologic information. Differences in the tissue contrast and brightness/darkness of the T2-weighted images can be attributed to the properties of the tissue and pulse sequences used, or more simply which scan parameters are chosen. Prostate tumor lesions appear conspicuously dark on T2 images.

Diffusion-weighted imaging (DWI)

DWI measures the diffusion of water molecules in a tissue using MRI. This random jiggling of water molecules is also known as "Brownian motion" *. In a malignant tissue the Brownian motion is impeded by cellular compactness within the tumor and measurement of this diffusion can be an indicator of tumor aggressiveness. The procedure is completely non-invasive and allows studying the prostate in closer detail. 

Dynamic contrast-enhanced imaging (DCE)

DCE is performed by the intravenous injection of a contrast agent to improve the tissue visibility through contrast using a gadolinium-based compound. Tumors enhance and wash out quickly with the intravenous contrast. DCE is effective at picking up contrast images for newly formed blood vessels in the tumors (all solid tumors develop new blood vessels, a process called "neoangiogenesis" to provide oxygen and nutrients to support the accelerated tumor growth).